MARKET

ESPR

ESPR

Esperion Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.58
-0.52
-4.30%
After Hours: 11.71 +0.13 +1.12% 16:59 09/24 EDT
OPEN
12.03
PREV CLOSE
12.10
HIGH
12.27
LOW
11.56
VOLUME
529.47K
TURNOVER
--
52 WEEK HIGH
39.50
52 WEEK LOW
10.99
MARKET CAP
327.45M
P/E (TTM)
-0.9554
1D
5D
1M
3M
1Y
5Y
10 Best Healthcare Stocks to Buy According to Matthew Halbower’s Pentwater Capital Management
In this article, we discuss the 10 best healthcare stocks to buy according to Matthew Halbower’s Pentwater Capital Management. If you want to skip our detailed analysis of Halbower’s history, investment philosophy, and hedge fund performance, go directly t...
Insider Monkey · 2d ago
Goldman Sachs Adjusts Price Target on Esperion Therapeutics to $8 From $16, Maintains Sell Rating
MT Newswires · 4d ago
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 09/14 11:50
20 Stocks Moving in Friday's Pre-Market Session
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) rose 29.6% to $11.26 in pre-market trading. Iveric Bio recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
Benzinga · 09/10 11:02
'3 "Strong Buy" Stocks Flirting With a Bottom' -TipRanks
https://www.tipranks.com/news/article/3-strong-buy-stocks-flirting-with-a-bottom
Benzinga · 09/09 14:52
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Benzinga · 09/09 12:17
Consumer discretionary stocks most shorted right now: S&P Global
Short bets have risen against consumer discretionary stocks as stimulus efforts have faded, a new S&P Global Market Intelligence report found.
Yahoo Finance · 09/08 16:40
Esperion Therapeutics (ESPR) Down 5.9% Since Last Earnings Report: Can It Rebound?
Zacks.com · 09/02 15:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ESPR. Analyze the recent business situations of Esperion Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ESPR stock price target is 42.45 with a high estimate of 114.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 239
Institutional Holdings: 34.78M
% Owned: 122.99%
Shares Outstanding: 28.28M
TypeInstitutionsShares
Increased
42
1.69M
New
18
755.83K
Decreased
44
1.13M
Sold Out
31
1.64M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
President/Chief Executive Officer/Director
Sheldon Koenig
Chief Financial Officer
Richard Bartram
Other
JoAnne Foody
Other
Ashley Hall
Lead Director/Independent Director
Nicole Vitullo
Director
Jeffrey Berkowitz
Independent Director
Alan Fuhrman
Independent Director
Antonio Gotto
Independent Director
Mark McGovern
Independent Director
Jay Shepard
Independent Director
Tracy Woody
No Data
About ESPR
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.

Webull offers kinds of Esperion Therapeutics Inc stock information, including NASDAQ:ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.